Plinabulin plus docetaxel promising in second-, third-line NSCLC treatment

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site

Sep 20 / Springer Healthcare

Plinabulin plus docetaxel promising in second-, third-line NSCLC treatment

Oncology Lung Cancer ESMO-2021

Description

Gilberto Lopes shares his thoughts on the DUBLIN-3 trial investigating the addition of the novel agent plinabulin to docetaxel in individuals who have received one or two prior lines of therapy for advanced non-small-cell lung cancer that is wild-type for EGFR.

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.